A5083976350- Lung Cancer Treatments and Mutations
- Cancer Immunotherapy and Biomarkers
- Occupational and environmental lung diseases
- Lung Cancer Research Studies
- Lung Cancer Diagnosis and Treatment
- Pleural and Pulmonary Diseases
- Medical Imaging and Pathology Studies
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Hippo pathway signaling and YAP/TAZ
- Cancer Genomics and Diagnostics
- Pancreatic and Hepatic Oncology Research
- Radiation Dose and Imaging
- Hepatocellular Carcinoma Treatment and Prognosis
- Radiomics and Machine Learning in Medical Imaging
- Chronic Lymphocytic Leukemia Research
- Melanoma and MAPK Pathways
- Cancer Research and Treatments
- Viral-associated cancers and disorders
- Soft tissue tumor case studies
- Ocular Oncology and Treatments
- Neuroblastoma Research and Treatments
- Immune Cell Function and Interaction
- Cancer-related Molecular Pathways
- Cancer therapeutics and mechanisms
- Gastric Cancer Management and Outcomes
Hôpital Bichat-Claude-Bernard
2015-2024
Université Claude Bernard Lyon 1
2015-2024
Inserm
2015-2024
Institut Curie
2018-2024
Assistance Publique – Hôpitaux de Paris
2015-2024
Centre d'Investigation Clinique - Innovation Technologique
2018-2024
Centre d'Investigation Clinique Bichat
2017-2024
Université Paris Cité
2015-2023
Université Paris Sciences et Lettres
2023
Délégation Paris 7
2015-2022
Immune checkpoint inhibitors (ICIs) targeting the PD-1/PD-L1 axis induce sustained clinical responses in a sizable minority of cancer patients. We found that primary resistance to ICIs can be attributed abnormal gut microbiome composition. Antibiotics inhibited benefit patients with advanced cancer. Fecal microbiota transplantation (FMT) from who responded into germ-free or antibiotic-treated mice ameliorated antitumor effects PD-1 blockade, whereas FMT nonresponding failed do so....
<h3>Importance</h3> Derived neutrophils/(leukocytes minus neutrophils) ratio (dNLR) and lactate dehydrogenase (LDH) level have been correlated with immune checkpoint inhibitor (ICI) outcomes in patients melanoma. <h3>Objective</h3> To determine whether pretreatment dNLR LDH are associated resistance to ICIs advanced non–small cell lung cancer (NSCLC). <h3>Design, Setting, Participants</h3> Multicenter retrospective study a test (n = 161) validation set 305) treated programmed death...
Hyperprogressive disease (HPD) is a new pattern of progression recently described in patients with cancer treated programmed cell death 1 (PD-1) and ligand (PD-L1) inhibitors. The rate outcome HPD advanced non-small lung (NSCLC) are unknown.To investigate whether observed NSCLC PD-1/PD-L1 inhibitors compared single-agent chemotherapy there an association between treatment HPD.In this multicenter retrospective study that included August 4, 2011, April 5, 2017, the setting was pretreated who...
<h3>Background</h3> Paraneoplastic syndromes (PNS) are autoimmune disorders specifically associated with cancer. There few data on anti-PD-1 or anti-PD-L1 immunotherapy in patients a PNS. Our objective was to describe the outcome for pre-existing newly diagnosed PNS following initiation of immunotherapy. <h3>Methods</h3> We included all adult (aged ≥18) treated solid tumor, PNS, and registered French pharmacovigilance databases. Patients were allocated cohorts 1 2 if had been before vs....
To report efficacy and tolerance of nivolumab or pembrolizumab, PD-1 inhibitors, in people living with HIV (PLWHIV) cancer. Series PLWHIV cancer patients treated anti-PD1 agents real-life clinical practice. From May 2014 to January 2019, 575 HIV-infected have been discussed the French CANCERVIH national multidisciplinary board included network database. Twenty-three were immune checkpoint inhibitors daily We demographic characteristics, CD4 T-cell counts, viral loads, safety data these 23...
There is a compelling need for approaches to predict the efficacy of immunotherapy drugs. Tumor-on-chip technology exploits microfluidics generate 3D cell co-cultures embedded in hydrogels that recapitulate simplified tumor ecosystems. Here, we present development and validation lung tumor-on-chip platforms quickly precisely measure ex vivo effects immune checkpoint inhibitors on T cell-mediated cancer death by exploiting power live imaging advanced image analysis algorithms. The integration...
<b><i>Introduction:</i></b> High-grade lung neuroendocrine tumours with carcinoid morphology have been recently reported; they may represent the thoracic counterparts of grade 3 digestive tumours. We aimed to study their genetic landscape including analysis tumoral heterogeneity. <b><i>Methods:</i></b> Eleven patients high-grade (&#x3e;20% Ki-67 and/or &#x3e;10 mitoses) a were included. analysed copy number variations, somatic...
Hyperprogressive disease (HPD), fast progression (FP), and early death (ED) have been described in 13.8%, 4.7%, 5.6% 5.1%, 2.8%, 6.8%, respectively, of patients with non-small-cell lung cancer (NSCLC) treated single-agent programmed cell ligand 1 inhibitors (ICI) or chemotherapy, respectively. Whether FP/ED HPD represent overlapping patterns is unknown.FP, ED, were retrospectively assessed NSCLC ICI chemotherapy. Eligibility required 2 computed tomography (CT) scans before CT scan during...
Background: Immune checkpoint inhibitors (ICIs) have been a major advance in treating non-small-cell lung cancer (NSCLC). Programmed cell death protein-1/programmed death-ligand 1 blockade enhances immune function, mediating anti-tumor activity, yet causing immune-related adverse events (irAEs). We investigated the prognostic role of Grade 3–4 irAEs on overall survival (OS). Methods: This observational study recruited advanced NSCLC patients who received ICIs at Bichat-Claude Bernard...
RASSF1A, a tumor suppressor gene, is frequently inactivated in lung cancer leading to YAP-dependent epithelial-mesenchymal transition (EMT). Such effects are partly due the inactivation of anti-migratory RhoB GTPase via inhibitory phosphorylation GEF-H1, GDP/GTP exchange factor for RhoB. However, kinase responsible RhoB/GEF-H1 RASSF1A-depleted cells remained unknown. NDR1/2 by siRNA or shRNA on transition, invasion, xenograft formation and growth SCID-/- Beige mice, apoptosis, proliferation,...
The role of immune checkpoints (ICPs) in both anti-HIV T cell exhaustion and HIV reservoir persistence, has suggested that an cure therapeutic strategy could involve ICP blockade. We studied the impact anti-PD-1 therapy on reservoirs anti-viral responses people living with treated for cancer. At several timepoints, we monitored CD4 counts, plasma HIV-RNA, associated (CA) HIV-DNA, EBV, CMV, HBV, HCV, HHV-8 viral loads, activation markers, expression virus-specific cells. Thirty-two patients...
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are approved for second-line treatment of EGFR wild-type ( -wt) nonsmall cell lung cancer (NSCLC). However, results from randomised trials performed to compare EGFR-TKIs with chemotherapy in this population did not show any survival benefit. In the era immunotherapy, many drugs EGFR- wt NSCLC and there is a need reassess role setting. The Biomarkers France study large nationwide cohort patients tested mutations. We used...
The Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS/NCT00651456) phase 3 trial demonstrated the superiority of bevacizumab plus pemetrexed-cisplatin triplet over chemotherapy alone in 448 malignant pleural mesothelioma (MPM) patients. Here, we evaluated prognostic role Hippo pathway gene promoter methylation.Promoter methylations were assayed using methylation-specific polymerase chain reaction samples from 223 MAPS patients, evaluating their value for overall survival (OS) and...
Background The optimal treatment for patients with severe coronavirus-19 disease (COVID-19) and hyper-inflammation remains debated. Material methods A cohort study was designed to evaluate whether a therapeutic algorithm using steroids or without interleukin-1 antagonist (anakinra) could prevent death/invasive ventilation. Patients ≥5-day evolution since symptoms onset, (CRP≥50mg/L), requiring 3–5 L/min oxygen, received methylprednisolone alone. needing ≥6 + subcutaneous anakinra daily...